Table 3 Selected patient, tumor and treatment characteristics for patients who developed a IBTR
Initials | Age (years) | Grade | Path | pT | pN | ER/PR status | Ki-67 | HER2 status | Molecular Group | Systemic tmt | Time to IBTR (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|
F.R. | 45 | 3 | D | is | X | NA | NA | NA | NA | None | 68.8 |
A.A. | 68 | 3 | D | is | 0 | Positive | NA | NA | NA | None | 45.9 |
R.B. | 50 | 2 | D | 2 | 1a | Positive | 5% | Negative | Luminal A | Chemo-horm | 30.6 |
D.M. | 56 | 2 | D | 2 | 0 | Positive | 40% | Positive | Luminal B | Chemo-horm | 20.2 |